| __timestamp | Merck & Co., Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 16768000000 | 14400000 |
| Thursday, January 1, 2015 | 14934000000 | 33800000 |
| Friday, January 1, 2016 | 13891000000 | 35900000 |
| Sunday, January 1, 2017 | 12775000000 | 1254000 |
| Monday, January 1, 2018 | 13509000000 | 4889000 |
| Tuesday, January 1, 2019 | 14112000000 | 7400000 |
| Wednesday, January 1, 2020 | 13618000000 | 10100000 |
| Friday, January 1, 2021 | 13626000000 | 14300000 |
| Saturday, January 1, 2022 | 17411000000 | 23200000 |
| Sunday, January 1, 2023 | 16126000000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for evaluating a company's financial health. Over the past decade, Merck & Co., Inc. and Neurocrine Biosciences, Inc. have shown contrasting trends in their cost of revenue. From 2014 to 2023, Merck's cost of revenue fluctuated, peaking in 2022 with a 19% increase from its lowest point in 2017. In contrast, Neurocrine Biosciences experienced a dramatic rise, with its cost of revenue surging by over 2,700% from 2017 to 2023. This stark difference highlights the diverse strategies and market conditions faced by these companies. While Merck's cost control reflects its established market presence, Neurocrine's increase suggests aggressive expansion and investment in new ventures. These insights provide a window into the strategic decisions shaping the future of these pharmaceutical giants.
Cost of Revenue Comparison: Merck & Co., Inc. vs BeiGene, Ltd.
Analyzing R&D Budgets: Merck & Co., Inc. vs Neurocrine Biosciences, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and Jazz Pharmaceuticals plc's Expenses
Analyzing Cost of Revenue: Merck & Co., Inc. and Amneal Pharmaceuticals, Inc.
Cost Insights: Breaking Down Merck & Co., Inc. and PTC Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Merck & Co., Inc. and Mesoblast Limited
Cost of Revenue: Key Insights for Merck & Co., Inc. and Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Jazz Pharmaceuticals plc
Neurocrine Biosciences, Inc. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs CRISPR Therapeutics AG
Neurocrine Biosciences, Inc. vs Perrigo Company plc: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.